Johann De Bono, MD
National Health Service, United Kingdom · Royal Marsden NHS Foundation Trust · Institute of Cancer Research, Royal Marsden Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Johann De Bono, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:07 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT06126731 · Combination Study of Antibiotics With Enzalutamide (PROMIZE)Institute of Cancer Research, United Kingdom · recruiting · Metastatic Castration-Resistant Prostate Cancer (mCRPC) · principal investigator
- Ph1/Ph2NCT04458311 · Abiraterone Acetate in Combination With TildrakizumabInstitute of Cancer Research, United Kingdom · terminated · Metastatic Castration Resistant Prostate Cancer · study director
- Ph1/Ph2NCT03568656 · Study to Evaluate CCS1477 in Advanced TumoursCellCentric Ltd. · completed · Metastatic Castration-Resistant Prostate Cancer, Metastatic Breast Cancer, Non-small Cell Lung Cancer · principal investigator
- Ph1/Ph2NCT03177187 · Combination Study of AZD5069 and Enzalutamide.Institute of Cancer Research, United Kingdom · terminated · Metastatic Castration Resistant Prostate Cancer · principal investigator
- Ph1NCT01337518 · A Phase 1a/1b Study to Evaluate the Safety of EZN-4176, in Adult Patients With Castration-Resistant Prostate CancerEnzon Pharmaceuticals, Inc. · suspended · Prostatic Neoplasm · principal investigator
- Ph1NCT00794131 · Safety Study of GL-ONC1, an Oncolytic Virus, in Patients With Advanced Solid TumorsGenelux GmbH · completed · Advanced Cancers (Solid Tumors) · principal investigator
- Ph1NCT00748891 · DCE CT/MRI Scanning Study in Patients With Solid Tumours (AstraZeneca and Royal Marsden Hospital Imaging Study)AstraZeneca · completed · Cancer · principal investigator
- Ph1NCT00516724 · Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or PaclitaxelAstraZeneca · completed · Triple Negative Metastatic Breast Cancer, Advanced Ovarian Cancer, Carboplatin · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:07 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.